3 Over the Counter Drug Maker, Specialty Fluorine Chemicals Maker and Electric Motors Maker Stocks With a Strong Future Roadmap: Marksans Pharma, Navin Fluorine International and Kirloskar Electric Company
- November 5, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Marksans Pharma, Navin Fluorine International and Kirloskar Electric Company: ROE of 12.3% to 16.7% and FY22 to FY26 revenue CAGR of 7.3% to 22.7%. Prices as of 4 Nov 2026.
Quick Answer
The three OTC drug, fluorine chemical and motor stocks to watch are Marksans Pharma, Navin Fluorine International and Kirloskar Electric Company. Their return on equity ranges from 12.3% to 16.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.3% to 22.7%. Navin Fluorine International leads on both return on equity at 16.7% and revenue growth at 22.7% a year. Prices are based on the 4 November 2026 close, and this article is educational, not investment advice.
OTC drug, fluorine chemical and motor stocks offer a focused view of a sector where demand keeps widening. Marksans Pharma, Navin Fluorine International and Kirloskar Electric Company cover an over the counter drug maker, a specialty fluorine chemicals maker and an electric motors maker.
This list covers three OTC drug, fluorine chemical and motor stocks with complete current figures: Marksans Pharma, Navin Fluorine International and Kirloskar Electric Company. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are OTC Drug, Fluorine Chemical and Motor Stocks?
OTC drug, fluorine chemical and motor stocks are listed companies that make over-the-counter and prescription formulations, produce refrigerant gases and specialty fluorochemicals, and build electric motors, alternators and transformers. Their earnings depend on export approvals, global chemical orders and industrial and rail investment.
OTC Drug, Fluorine Chemical and Motor Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Marksans Pharma | 301.65 | 12,994 | 24.9 | 35.7 | 13.8 | 0.11 |
| Navin Fluorine International | 8,777 | 41,847 | 53.0 | 35.1 | 16.7 | 0.32 |
| Kirloskar Electric Company | 107.48 | 811 | 108.5 | 43.9 | 12.3 | 0.76 |
On valuation, Marksans Pharma trades at a P/E below the industry P/E, while Navin Fluorine International and Kirloskar Electric Company trade above it, which reflects the growth the market already expects. Readers comparing OTC drug, fluorine chemical and motor stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do OTC Drug, Fluorine Chemical and Motor Stocks Have a Strong Roadmap in India?
OTC drug, fluorine chemical and motor stocks have a strong roadmap in India because steady demand for generics overseas, wider specialty chemical applications and growing industrial and rail investment keep widening the market for these companies.
- Generics. Regulated markets buy dependable supply.
- Fluorine chemicals. Cooling and pharma users need specialty inputs.
- Electric motors. Industry and railways need dependable machines.
Why Marksans Pharma Features Among These OTC Drug, Fluorine Chemical and Motor Stocks
Among the OTC drug, fluorine chemical and motor stocks on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.
In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%.
Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7.
Roadmap: The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What to watch: Track export growth, new product approvals and plant utilisation.
Why Navin Fluorine International Features Among These OTC Drug, Fluorine Chemical and Motor Stocks
Among the pharma, chemistry and electrical shares on this list, Navin Fluorine International is a specialty fluorine chemicals company that makes refrigerant gases, specialty fluorochemicals, and custom research and manufacturing services for pharma and agrochemical clients.
The company has a return on equity of 16.7%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 41,847 crore. The stock trades at a P/E of 53.0, above the industry P/E of 35.1.
Revenue rose from Rs 1,493 crore in FY22 to Rs 3,379 crore in FY26, a compound annual growth rate of 22.7%. Net profit grew from Rs 263 crore in FY22 to Rs 664 crore in FY26, which works out to a compound annual growth rate of 26.0%. In the June 2026 quarter, revenue grew 46.1% year on year to Rs 1,080 crore, while net profit rose 107.7% to Rs 243 crore.
Roadmap: Growth is driven by specialty chemicals, contract manufacturing for global partners and new fluorination capacity. The company has also added capacity for products linked to battery and clean energy applications.
What to watch: Check the ramp-up of new capacity and the share of the contract manufacturing business in revenue.
Why Kirloskar Electric Company Features Among These OTC Drug, Fluorine Chemical and Motor Stocks
Among the three companies on this list, Kirloskar Electric Company is a Bengaluru-based maker of electric motors, alternators, generators, transformers and related electrical equipment for industry, railways and power customers.
Revenue rose from Rs 454 crore in FY22 to Rs 600 crore in FY26, a compound annual growth rate of 7.3%. Net profit grew from Rs 3.7 crore in FY25 to Rs 8.4 crore in FY26, a rise of 124.7%.
The company has a return on equity of 12.3%, a debt to equity ratio of 0.76 and a market capitalisation of Rs 811 crore. The stock trades at a P/E of 108.5, above the industry P/E of 43.9.
Roadmap: The company is widening its range of motors and generators and growing its supply for industrial, railway and power projects. Long industry experience and a wide product range support its order book.
What to watch: Track order inflows, execution and demand from power and railway customers.
Marksans Pharma vs Navin Fluorine International vs Kirloskar Electric Company on Key Financials
The table below sets the three OTC drug, fluorine chemical and motor stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Marksans Pharma | 1,533 | 3,033 | 18.6% | 420 | 13.8% |
| Navin Fluorine International | 1,493 | 3,379 | 22.7% | 664 | 19.6% |
| Kirloskar Electric Company | 454 | 600 | 7.3% | 8.4 | 1.4% |
Navin Fluorine International posts the highest return on equity in this group at 16.7%. Navin Fluorine International combines the largest FY26 revenue at Rs 3,379 crore with the fastest revenue growth, a 22.7% compound annual rate. A useful habit with OTC drug, fluorine chemical and motor stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in OTC Drug, Fluorine Chemical and Motor Stocks
Every theme carries risks that deserve a check before any decision. For these OTC drug, fluorine chemical and motor stocks, the main points are: Long-term pharma, chemistry and electrical shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Order timing. Project awards can shift between periods.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter OTC drug, fluorine chemical and motor stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on OTC Drug, Fluorine Chemical and Motor Stocks
OTC drug, fluorine chemical and motor stocks reward patient research into demand, execution and financial strength. Marksans Pharma, Navin Fluorine International and Kirloskar Electric Company each have a clear plan to grow. Based on the 4 November 2026 close, Marksans Pharma trades at Rs 301.65, Navin Fluorine International at Rs 8,777 and Kirloskar Electric Company at Rs 107.48.
Download the Univest iOS App or Univest Android App to track OTC drug, fluorine chemical and motor stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are OTC drug, fluorine chemical and motor stocks?
Ans. OTC drug, fluorine chemical and motor stocks are listed companies that make over-the-counter and prescription formulations, produce refrigerant gases and specialty fluorochemicals, and build electric motors, alternators and transformers. Their earnings depend on export approvals, global chemical orders and industrial and rail investment. This list looks at three of them, Marksans Pharma, Navin Fluorine International and Kirloskar Electric Company, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.
Which OTC drug, fluorine chemical and motor stocks are covered in this list?
Ans. This list covers Marksans Pharma, Navin Fluorine International and Kirloskar Electric Company. Based on the 4 November 2026 close, Marksans Pharma traded at Rs 301.65, Navin Fluorine International at Rs 8,777 and Kirloskar Electric Company at Rs 107.48. Their return on equity ranges from 12.3% to 16.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.3% to 22.7%.
Why do OTC drug, fluorine chemical and motor stocks have a strong future roadmap in India?
Ans. OTC drug, fluorine chemical and motor stocks have a strong roadmap in India because steady demand for generics overseas, wider specialty chemical applications and growing industrial and rail investment keep widening the market for these companies. The main drivers are as follows. Generics. Regulated markets buy dependable supply. Fluorine chemicals. Cooling and pharma users need specialty inputs. Electric motors. Industry and railways need dependable machines. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Marksans Pharma performed financially?
Ans. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
How has Navin Fluorine International performed financially?
Ans. Revenue rose from Rs 1,493 crore in FY22 to Rs 3,379 crore in FY26, a compound annual growth rate of 22.7%. Net profit grew from Rs 263 crore in FY22 to Rs 664 crore in FY26, which works out to a compound annual growth rate of 26.0%. In the June 2026 quarter, revenue grew 46.1% year on year to Rs 1,080 crore, while net profit rose 107.7% to Rs 243 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 41,847 crore. The stock trades at a P/E of 53.0, above the industry P/E of 35.1. Looking ahead, growth is driven by specialty chemicals, contract manufacturing for global partners and new fluorination capacity. The company has also added capacity for products linked to battery and clean energy applications.
How has Kirloskar Electric Company performed financially?
Ans. Revenue rose from Rs 454 crore in FY22 to Rs 600 crore in FY26, a compound annual growth rate of 7.3%. Net profit grew from Rs 3.7 crore in FY25 to Rs 8.4 crore in FY26, a rise of 124.7%. The company has a return on equity of 12.3%, a debt to equity ratio of 0.76 and a market capitalisation of Rs 811 crore. The stock trades at a P/E of 108.5, above the industry P/E of 43.9. Looking ahead, the company is widening its range of motors and generators and growing its supply for industrial, railway and power projects. Long industry experience and a wide product range support its order book.
What risks should investors check before buying OTC drug, fluorine chemical and motor stocks?
Ans. Investors should check a few risks before buying OTC drug, fluorine chemical and motor stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Order timing. Project awards can shift between periods. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of OTC drug, fluorine chemical and motor stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
